Pituitary Flashcards
When are pituitary adenomas removed?
- Normally asymptomatic
- Indication for treatment if it causes mass effect (headache, visual changes, pituitary compression affecting hormone function)
- Surgery: transphenoidal
- Can use radiotherapy + surgery
- Temozolamide can be used, alkylating agent
What is the function of ADH?
To reabsorb and concentrate water. Impaired ADH function causes diabetes insipidus which cause polyuria (dilute urine)
Difference between central and nephrogenic diabetes insipidus.
- Central DI: occurs due to the posterior pituitary not producing ADH. ADH renal receptors still working.
- With water deprivation test, urine osmolality does not improve but with desmopressin, urine osmolality improves.
- Hypertonic saline infusion test to diagnose central - measurement of copeptin (c terminal segment of ADH) in blood, low level and fails to rise in central DI
Causes: craniopharyngioma, sheehan syndrome, pituitary haemorrhage.
ADH levels are low. - Nephrogenic DI: occurs due to defective ADH receptors in distal tubules and collecting duct. Urine osmolality does not improve with water deprivation or desmopressin administration.
Causes: medications like lithium, demeclocycline (used for SIADH as it acts on the ADH receptors and reduce their responsiveness), renal disease. ADH levels are normal or increased to compensate for high urine output.
Symptoms: polyuria, polydypsia, nocturia, severe dehydration.
What is a new way to diagnose central diabetes insipidus?
Hypertonic saline infusion test with copeptin measurement (low levels fails to rise in central DI)
- Being used over water deprivation as it takes a shorter time to perform
- Involves infusion of 250mL bolus of hypertonic (3%) saline then infusion 0.15ml/kg/min with blood tests every 30 mins. Test finished when serum sodium reaches >150mmol/L. Measure of copeptin (c terminal segment of arginine vasopressin prohormone) level in blood at end of test. Failure of copeptin to rise during test to >4.9pmol/L indicates partial/total central DI
Copeptin = ADH
- If copeptin > 21.4 (without water deprivation): nephrogenic DI (as ADH is high)
- If copeptin <2.6 (with prior fluid deprivation): Complete central DI (as ADH remains low)
- Stimulated copeptin
If stimulated copeptin < 4.9: partial central DI
If stimulated copeptin >4.9: primary polydypsia
Treatment of central and nephrogenic DI
- Central: desmopressin
SE: hyponatremia
Other indications of desmopressin include haemophilia A, von willebrand, sleep enuresis, chlorpropamide - Nephrogenic: salt restriction and water intake.
Discontinue meds, eg: llithium
Thiazide diuretics
Nsaids
Amiloride: indicated in patients with lithium associated (potassium sparing agent)
In adrenal insufficiency, what glucocorticoids can you use?
- Pred 5mg/day
- Hydrocortisone 20-30mg/day in divided doses
- Cortisone acetate 25-37.5mg in divided dose
- Dex 0.5-1mg day
- Hydrocortisone and cortisone acetate provide the most physiological replacement.
- Dex not usually used to treat secondary hypocortisolism as correct dose difficult
What happens in hypopituitarism for prolactin?
Unlike most pituitary hormones the hypothalamus INHIBITS prolactin secretion, through prolactin inhibitory factor (dopamine)
A lesion of the pituitary stalk leads to loss of other pituitary hormones but increases in prolactin
Hypopituitarism = everything low except prolactin is high
What inhibits prolactin and what inhibits growth hormone?
Prolactin inhibited by dopamine. Therefore in prolactinoma, you give dopamine agonists. This is also why antipsychotics which are dopamine antagonist can increase prolactin (not usually more than 2-4x increase)
- Prolactin increases with stress, oestrogen and antipsychotics
Growth hormone is inhibited by somatostatin and thus in acromegaly, you give somatosatin.
Clinical signs and treatment of prolactinomas.
Hyperprolactinemia inhibits pulsatile gonadotropin release and thus can cause hypogonadism
- Pre-menopausal: amenorrhoea, infertility, galactorrhoea
- Post menopausal: mass effect
- Men: hypogonadism, reduced libido, impotence - often not diagnosed until tumour is large often with visual change
Tx: medical and then surgery.
- Dopamine receptor agonist: bromocriptine or cabergoline.
- Carbegoline: long effect, less side effects and preferred over bromcriptine who has SE including nausea, postural hypotension, nasal stiffness
- If not effective, surgery + radiotherapy
SE of dopamien receptor agonist include pulmonary and retroperitoneal fibrosis, pleural and pericardial effusion and constrictive pericarditis
Diagnosis of acromegaly
- Elevated IGF-1: best single test and then conduct OGTT
- OGTT with baseline GH and GH after 2 hours: most specific test
If GH suppressed: acromegaly ruled out
If GH not suppressed: confirmed acromegaly - Pituitary MRI for pituitary adenoma
If normal for extrapitutiary cause, CT chest/abdo, measure GHRH
If IGF1 normal- acromegaly excluded
If IGF1 elevated, proceed to OGTT
If normal suppression: GH <1; acromegaly excluded. Otherwise proceed to MRI pituitary
If no pituitary mass noted, consider empty sella
If no abnormalities noted on MRI, consider pan CT and GHRH measurement to look for malignancy and extrapituitary acromgelay
Treatment of Acromegaly
surgery –> somatostatin analogue –> pegvisomant
- Primary Treatment: Transsphenoidal resection of pituitary tumour, success 80%
- Can also use radiotherapy to shrink tumour
Medical Treatment:
- Octreotide: long acting analogue of somatostatin , now available as monthly depot injection
SE: cholelithiasis/ gallstones, abdominal pain and diarrhoea/steatorrhoea, restores fertility (need to use contraceptive), bradycardia, hypothyroidism, hair loss
- Pegvisomant: GH receptor antagonist
Effective in normalising IGF1
Blocks peripheral production of insulin-like growth factor 1 (IGF-1)
Does not affect size of pituitary tumour or growth hormone secretion
Useful for resistant disease as is most potent agent for lowering IGF-1 levels
Although it reduces IGF-1 levels, GH level increase and adenoma could grow (can be combined with somatostatin analgoues)
SE: transaminitis, lipohypertrophy
Pegvisomant effectively lowers IGF-1 levels, but patients on pegvisomant have risk of tumor growth because the medication works in the peripheral tissues as an antagonist to GH and does not decrease GH production by the tumor. - Dopamine agonists (cabergoline) useful if co-secrete prolactin mainly, reduce tumour size and GH secretion
Used in patients with prolactin and growth hormone co-secretion
Added to somatostatin analogue when monotherapy is not effective
SE: restores fertility (need to use contraceptive), impulse control disorder in those with neuropsychiatric conditions, nausea, vomiting, abdominal pain, constipation, headache, dizziness, orthostatic hypotension, weakness, fatigue, nasal congestion, peripheral oedema
Radiotherapy: for failed surgery, slow effect
What are the causes of cushing syndrome?
- Iatrogenic: exogenous glucocorticoids
- ACTH dependent (high normal or increased ACTH); normally due to pituitary adenoma
- ACTH independent (low): adrenal adenoma/carcinoma and require adrenal imaging
Clinical features of cushings
- Early: weight gain (centripetal), hypertension, glucose intolerance, mood, attention and concentration change, androgen excess, back pain
- Later: bruising, thin skin, osteoporosis with fractures, muscle weakness, infections
What clues indicate a TSH secreting pituitary tumour?
Treatment
- Clue is presence of hyperthyroidism but TSH is not suppressed
- A TSH-secreting pituitary adenoma should be suspected in hyperthyroid patients with diffuse goiter and no extrathyroidal manifestations of Graves’ disease, who have high serum free T4 and T3 concentrations and unsuppressed (normal or high) serum TSH concentrations, particularly in the presence of headache or clinical features of concomitant hypersecretion of other pituitary hormones (eg, symptoms of acromegaly). The subsequent finding of a pituitary macroadenoma by magnetic resonance imaging (MRI) is very strong evidence that the patient has a TSH-secreting pituitary adenoma, particularly in the presence of an elevated alpha subunit.
Surgery, radiotherapy, octreotide (somatostatin)
What does TRH (thyrotropin releasing hormone) secrete?
TSH and prolactin.
An increase in TRH levels can result in the development of galactorrhoea because it stimulates prolactin levels.
What inhibits TSH secretion?
Dopamine
Somatostatin
Glucocorticoids
What is the function of GNRH?
- Stimulates FSH and LH secretion
LH - triggers ovulation in females, stimulates testosterone in the Leydig cells in males
FSH - stimulates the maturation of germ cells in both female + male - During breast feeding, high prolactin levels cause suppressed GNRH secretion which results in the development of lactational amenorrhea
- Pulsatile GNRH secretion is responsible for puberty and reproductive function
During pregnancy, prolactin levels go up. After the baby is born, there is a sudden drop in estrogen and progesterone. High prolactin levels trigger the body to make milk for breastfeeding
What can synthetic forms of GHRH (tesamorelin) be used for?
Synthetic forms of GHRH (tesamorelin) can be used for abdominal fat reduction in HIV associated lipodystrophy.
What is the role of somatostatin?
- Inhibits GH and TSH secretion
- Synthetic forms of somatostatin are used in the treatment of acromegaly, eg: octreotide
Function of growth hormone
Located in arcuate nucleus of hypothalamus.
Direct effects
- Increase lipolysis
- Decrease glucose uptake in the cells (increase insulin resistance)
- Increase protein synthesis
- Increase amino acid uptake
- Causes liver to release IGF-1 which induces cell division, protein synthesis and bone elongation.
Indirect effects
- Growth stimulation
- Anabolic effect on body
What stimulates and inhibits growth hormone levels?
Increases
- hypoglycaemia, fasting, exercise, sleep, sepsis. puberty, ckd, thyroid hormone, estrogen, testosterone, short term glucocorticoid exposure, ghrelin in the stomach (hunger hormone)
- Increased ghrelin, increased amino acids, decreased blood sugar, decreased fatty acids
Decreases
- Glucose, somatostatin, chronic glucocorticoid therapy, leptin, obesity
- decreased ghrelin, decreased amino acids increased blood sugar, increased fatty acid
What does CRH (corticotropin releasing hormone) do?
- Stimulate ACTH, MSH (melanocyte stimulating hormone), B-endorphin